In an attempt to address the lack of effective therapy for CCC, we performed a double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of G-CSF therapy with concomitant use of standard heart failure therapy in patients with CCC. This evidence concerns the gene CSF3 and heart failure.